根治性前列腺切除术后放疗患者接受18F-DCFPyL PSMA PET后管理变化及早期生化反应结局
这项前瞻性研究纳入100例根治性前列腺切除术后PSA复发(0.2-2.0 ng/mL)且未接受过治疗的患者,比较诊断CT与18F-DCFPyL PSMA PET/CT对管理意图的影响。PSMA PET/CT检出疾病的比例为46.9%,高于诊断CT的15.5%;PSMA后重大管理意图改变为12.5%,高于CT后的3.2%(P=0.010)。86例接受18F-DCFPyL引导放疗的患者中,55例未接受ADT或ADT后恢复,18个月PSA反应从0.32降至0.02 ng/mL。
要点
- PSMA PET/CT检出疾病46.9%,高于诊断CT的15.5%。
- PSMA后重大管理意图改变12.5%,高于CT后的3.2%(P=0.010)。
- 86例接受18F-DCFPyL引导放疗,55例未用ADT或ADT后恢复者18个月PSA从0.32降至0.02 ng/mL。
核心结论
- 18F-DCFPyL PET/CT对根治性前列腺切除术后PSA复发、考虑挽救性放疗患者的管理意图有显著影响。
- 疾病检出增加,尤其是盆腔淋巴结检出增加,导致盆腔照射和同期ADT使用增加。
- 接受18F-DCFPyL PET/CT分期的患者早期结果显示有利的PSA反应。
研究设计与样本
- 前瞻性研究纳入100例既往因前列腺癌行根治性前列腺切除术、PSA为0.2-2.0 ng/mL且未接受过治疗的患者。
- 所有患者接受诊断CT和PSMA PET/CT,并在3个时间点(原始、CT后、PSMA后)完成管理意图并比较。
- 报告98例患者,中位PSA为0.32 ng/mL(95%CI,0.28-0.36)。
- 呈现接受放疗且有6个月PSA反应数据的患者。
主要发现
- pT3a/b疾病占71.4%,国际泌尿病理学会分级组至少3级占59.2%。
- PSMA PET/CT检出疾病46.9%,诊断CT检出15.5%;PSMA PET中局部复发29.2%、盆腔淋巴结疾病29.6%。
- PSMA后重大管理意图改变为12.5%,CT后为3.2%(P=0.010);中度意图改变为31.3% vs. 13.7%(P=0.001)。
- 从原始到PSMA后意图,选择性盆腔放疗推荐从15.6%增至33.3%,淋巴结加强从0%增至22.9%,同期ADT使用从22.9%增至41.7%,原因是检出淋巴结疾病。
- 86例接受18F-DCFPyL引导放疗;55/86例未接受ADT或ADT后恢复,18个月PSA反应从0.32降至0.02 ng/mL,94.5%患者PSA不超过0.20 ng/mL,74.5%患者PSA不超过0.03 ng/mL。
关键数值与推荐
- PSMA PET/CT检出疾病46.9%,诊断CT检出15.5%。
- 重大管理意图改变PSMA后12.5% vs. CT后3.2%(P=0.010)。
- 中度管理意图改变PSMA后31.3% vs. CT后13.7%(P=0.001)。
- 选择性盆腔放疗推荐从15.6%增至33.3%,淋巴结加强从0%增至22.9%,同期ADT使用从22.9%增至41.7%。
- 55/86例未接受ADT或ADT后恢复者18个月PSA从0.32降至0.02 ng/mL,94.5%患者PSA不超过0.20 ng/mL,74.5%患者PSA不超过0.03 ng/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) tracers have increased sensitivity in the detection of prostate cancer, compared with conventional imaging. We assessed the management impact of 18F-DCFPyL PSMA PET/CT in patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) and report early biochemical response in patients who underwent radiation treatment. Methods: One hundred patients were enrolled into a prospective study, with a prior RP for prostate cancer, a PSA of 0.2-2.0 ng/mL, and no prior treatment. All patients underwent diagnostic CT and PSMA PET/CT, and management intent was completed at 3 time points (original, post-CT, and post-PSMA) and compared. Patients who underwent radiotherapy with 6-mo PSA response data are presented. Results: Ninety-eight patients are reported, with a median PSA of 0.32 ng/mL (95% CI, 0.28-0.36), pT3a/b disease in 71.4%, and an International Society of Urological Pathology grade group of at least 3 in 59.2%. PSMA PET/CT detected disease in 46.9% of patients, compared with 15.5% using diagnostic CT (PSMA PET, 29.2% local recurrence and 29.6% pelvic nodal disease). A major change in management intent was higher after PSMA than after CT (12.5% vs. 3.2%, P = 0.010), as was a moderate change in intent (31.3% vs. 13.7%, P = 0.001). The most common change was an increase in the recommendation for elective pelvic radiation (from 15.6% to 33.3%), nodal boost (from 0% to 22.9%), and use of concurrent androgen deprivation therapy (ADT) (from 22.9% to 41.7%) from original to post-PSMA intent because of detection of nodal disease. Eighty-six patients underwent 18F-DCFPyL-guided radiotherapy. Fifty-five of 86 patients either did not receive ADT or recovered after ADT, with an 18-mo PSA response from 0.32 to 0.02 ng/mL; 94.5% of patients had a PSA of no more than 0.20 ng/mL, and 74.5% had a PSA of no more than 0.03 ng/mL. Conclusion: 18F-DCFPyL PET/CT has a significant impact on management intent in patients being considered for salvage radiotherapy after RP with PSA recurrence. Increased detection of disease, particularly in the pelvic lymph nodes, resulted in increased pelvic irradiation and concurrent ADT use. Early results in patients who are staged with 18F-DCFPyL PET/CT show a favorable PSA response.
引用
- Ng M, Guerrieri M, Wong LM, et al. Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes. J Nucl Med. 2022. PMID: 35058320. doi:10.2967/jnumed.121.263521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。